Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Depreciation & Amortization (CF): 2019-2024

Historic Depreciation & Amortization (CF) for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $9.3 million.

  • Nurix Therapeutics' Depreciation & Amortization (CF) fell 15.29% to $2.0 million in Q3 2025 from the same period last year, while for Aug 2025 it was $9.2 million, marking a year-over-year increase of 5.35%. This contributed to the annual value of $9.3 million for FY2024, which is 23.70% up from last year.
  • Nurix Therapeutics' Depreciation & Amortization (CF) amounted to $9.3 million in FY2024, which was up 23.70% from $7.5 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Depreciation & Amortization (CF) registered a high of $9.3 million during FY2024, and its lowest value of $2.2 million during FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Depreciation & Amortization (CF) value was $7.5 million (recorded in 2023), while the average stood at $7.4 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Depreciation & Amortization (CF) dropped by 8.33% in 2020, and later spiked by 91.04% in 2022.
  • Over the past 5 years, Nurix Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $2.2 million in 2020, then increased by 27.27% to $2.8 million in 2021, then soared by 91.04% to $5.3 million in 2022, then soared by 40.83% to $7.5 million in 2023, then increased by 23.70% to $9.3 million in 2024.